Leukodystrophies

Slide 1 · Leukodystrophies

Molecular mechanisms, neuropathology and clinicopathologic diagnosis

Inherited disorders of myelin formation, turnover and maintenance

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain why inherited myelin defects cause progressive symmetric white matter disease.

Connect GALC, ARSA and ABCD1 defects to their characteristic pathology.

Differentiate globoid macrophages, metachromatic deposits and inflammatory demyelination.

Identify GFAP-, EIF2B- and PLP1-associated disorders and their diagnostic clues.

Slide 3 · Myelin is the central pathologic substrate

Oligodendrocytes generate and maintain CNS myelin.

Myelin surrounds axons and supports efficient impulse propagation.

Inherited defects can disturb synthesis, stability or lipid recycling.

Axon

Myelin lamellae

Insulation around axon

Schematic — not a diagnostic specimen

Slide 4 · Three failure points in white matter biology

Myelin formation

Myelin maintenance

Myelin lipid turnover

Disruption at any point can produce inherited white matter pathology.

A shared imaging phenotype does not imply a shared molecular defect.

Schematic

Slide 5 · Genetic metabolic disease: Principal targets

Disease group

Dominant cellular target

Key pathologic process

Neuronal storage diseases

Neurons

Intra-neuronal storage; Dysfunction and death

Leukodystrophies

Myelin / glial support

Defective generation, turnover or maintenance

Mitochondrial encephalomyopathies

Energy-dependent tissues

Failure of oxidative phosphorylation

Slide 6 · Leukodystrophy is not one molecular disease

Numerous monogenic disorders converge on cerebral white matter injury.

Some result from single-enzyme defects in myelin-associated lipids.

Others involve structural proteins, stress-response pathways or glial functions.

Classification by affected process complements classification by clinical age.

Slide 7 · Inherited leukodystrophy versus acquired demyelination

Feature

Typical leukodystrophy

Acquired demyelinating disease

Cause

Germline molecular defect

Acquired inflammatory or other injury

Clinical course

Often insidious and progressive

May be relapsing, focal or progressive

Imaging

Often diffuse and symmetric

Distribution often less symmetric

Caution

Phenotypic exceptions exist

MRI pattern alone is not diagnostic

Slide 8 · Why the presentation often begins in childhood

Myelin production and maturation are especially important during development.

Progressive injury can become apparent as motor abilities fail to develop or are lost.

Age of onset varies by disorder, genotype and residual function.

A late-onset phenotype does not exclude genetic white matter disease.

Slide 9 · Typical clinicopathologic evolution

Gene defect

Glial / lipid pathway defect

White matter injury

Neurologic decline

Insidious progression and symmetric imaging abnormalities are recurring clues.

The specific affected pathway determines extracerebral findings.

Schematic

Slide 10 · Reading a symmetric white matter MRI

Diffuse symmetric abnormality raises suspicion of an inherited or metabolic process.

Pattern recognition narrows the differential but does not establish etiology.

Peripheral neuropathy, adrenal signs and age of onset add discriminatory value.

Biochemical and molecular confirmation should follow the phenotype.

Slide 11 · Three biochemical archetypes

Krabbe

Galactocerebrosidase deficiency

Psychosine toxicity

Metachromatic

Arylsulfatase A deficiency

Sulfatide accumulation

X-linked ALD

ABCD1 transport defect

Very-long-chain fatty acids

Each disorder injures white matter through a distinct primary mechanism.

Slide 12 · Mechanism-guided diagnostic reasoning

Clinical tempo and age

MRI + peripheral / systemic clues

Targeted metabolites / enzymes

Molecular confirmation

Laboratory studies complement—not replace—the clinical and radiologic phenotype.

Enzyme pseudodeficiency must be considered in lysosomal disorders.

Schematic

Slide 13 · Krabbe disease: Molecular identity

Autosomal recessive lysosomal leukodystrophy associated with GALC deficiency.

GALC encodes galactocerebrosidase, an enzyme in galactolipid catabolism.

The disorder is also termed globoid cell leukodystrophy.

The key toxic metabolite is galactosylsphingosine (psychosine).

Slide 14 · Krabbe: The normal GALC reaction

Galactocerebroside

GALC enzymatic hydrolysis

Ceramide + galactose

Loss of GALC function impairs turnover of galactosylceramide-containing myelin lipids.

Terminology correction: The substrate is galactocerebroside—not glucocerebroside.

Schematic — reaction nomenclature corrected against GeneReviews

Slide 15 · Krabbe: Pathogenic lipid shunting

GALC deficiency

Impaired galactolipid processing

Psychosine accumulation

Glial cell toxicity

Psychosine injures oligodendrocytes and astrocytes.

Myelin integrity is lost as supporting glial cells deteriorate.

Schematic

Slide 16 · Krabbe: Glial toxicity leads to myelin loss

Psychosine is toxic to the cells that support white matter.

Oligodendrocyte depletion explains severe loss of CNS myelin.

Astrocytic involvement compounds tissue dysfunction.

Astrocyte / oligodendrocyte stress

Oligodendrocyte

Astrocyte

Schematic — not a diagnostic specimen

Slide 17 · Krabbe: Classic infantile course

The classical infantile form manifests during the first months of life.

Stiffness and weakness reflect early motor-system involvement.

The untreated infantile phenotype may deteriorate rapidly.

Later-onset phenotypes also occur; Early infancy is not universal.

Slide 18 · Krabbe: Clinical–anatomic correlations

Motor signs

White matter tract dysfunction

→ weakness and spasticity

Peripheral nerve

Myelin pathology outside CNS

→ peripheral neuropathy

Cognition / function

Progressive cerebral disease

→ neurologic decline

Both central and peripheral myelin pathology can be present in the same patient.

Slide 19 · Krabbe: Gross white matter pallor

Normal myelinated white matter loses its expected color.

Extensive myelin loss can produce a gray–yellow appearance.

Color alone cannot identify the genetic cause; Microscopy and testing are needed.

White matter

Myelin-rich → myelin-depleted

Schematic — not a diagnostic specimen

Slide 20 · Krabbe: Hallmark globoid macrophages

Engorged macrophages aggregate within diseased white matter.

Clusters may be seen in parenchyma and around blood vessels.

The globoid-cell pattern is diagnostically characteristic in context.

Globoid macrophages (schematic)

Engorged phagocytes aggregate in white matter

Schematic — not a diagnostic specimen

Slide 21 · Krabbe: Tissue response sequence

Psychosine-mediated injury

Myelin + oligodendrocyte loss

Macrophage recruitment

Globoid cell aggregates

Neurons and axons are relatively spared compared with myelin.

“Relative preservation” does not mean that axonal function is intact.

Schematic

Slide 22 · Krabbe: Expected anatomic pathology

Structure

Characteristic change

Functional inference

CNS myelin

Marked loss

Long-tract and cerebral dysfunction

Oligodendrocytes

Depletion

Impaired myelin maintenance

Macrophages

Globoid aggregates

Phagocytic response / storage

Peripheral nerves

Related myelin injury

Peripheral neuropathy

Axons / neurons

Relative preservation

Primary pathology is not neuronal storage

Slide 23 · Krabbe: Diagnostic evidence

Suggestive clinical pattern and abnormal white matter imaging establish suspicion.

GALC enzyme activity is evaluated in an appropriate biochemical specimen.

Psychosine measurement adds disease-relevant metabolic evidence.

Biallelic pathogenic GALC variants can establish molecular diagnosis.

Slide 24 · Krabbe: Why enzyme activity alone may mislead

Low measured GALC

Consider benign pseudodeficiency

Measure psychosine / assess genotype

Integrate with phenotype

Low GALC activity can occur without classic infantile Krabbe disease.

The interpretation must distinguish pathogenic variants from pseudodeficiency.

Schematic

Slide 25 · Teaching vignette: Severe infantile myelin disease

An infant develops rapidly progressive stiffness and weakness.

Brain white matter is diffusely abnormal; Peripheral nerves are involved.

The pathologic specimen shows engorged macrophages in aggregates.

Which enzyme and metabolite best explain this pattern?

Slide 26 · Case interpretation: Globoid cell leukodystrophy

Globoid macrophages point toward Krabbe disease.

GALC deficiency disrupts galactolipid catabolism.

Psychosine accumulation links metabolic failure to glial loss.

Confirm with appropriate biochemical and molecular testing.

Slide 27 · Metachromatic leukodystrophy: Definition

Autosomal recessive lysosomal disease caused by arylsulfatase A deficiency.

The ARSA enzyme initiates degradation of sulfate-containing lipids.

Undegraded sulfatides accumulate, particularly in myelin-rich tissues.

The name refers to the staining property of deposited lipid.

Slide 28 · MLD: The normal lysosomal reaction

Sulfatide substrate

Arylsulfatase A

Desulfated lipid

Subsequent breakdown

Enzyme deficiency blocks the first major desulfation step.

The metabolic bottleneck causes accumulation of sulfatide-rich material.

Schematic

Slide 29 · MLD: Substrate storage in lysosomes

Sulfatides accumulate when ARSA-mediated breakdown fails.

Stored lipid is toxic to myelin-bearing tissues.

Macrophages can contain membrane-bound lipid-rich vacuoles.

Lysosome

Accumulating substrate

Schematic — not a diagnostic specimen

Slide 30 · MLD: Why the CNS and PNS are involved

Myelin is particularly enriched in sulfatide-containing membranes.

The same enzyme is expressed in multiple tissues.

White matter pathology coexists with peripheral nerve deposition.

The distribution follows substrate biology, not merely brain anatomy.

Slide 31 · MLD: Histologic cascade

ARSA deficiency

Sulfatide retention

Demyelination / dysmyelination

Gliosis + macrophages

Gliosis is a reactive consequence of white matter injury.

Foamy or vacuolated macrophages reflect lipid-laden tissue responses.

Schematic

Slide 32 · MLD: Vacuolated white matter macrophages

Macrophage cytoplasm contains numerous vacuoles.

Membrane-bound vacuoles hold complex crystalloid sulfatide deposits.

These changes coexist with white matter loss and gliosis.

Vacuolated lipid-laden macrophages (schematic)

Lipid-filled cytoplasmic vacuoles

Schematic — not a diagnostic specimen

Slide 33 · Metachromasia is a chemical staining phenomenon

Certain dyes change their apparent absorption properties when bound to sulfatides.

Toluidine blue is a classic example used to demonstrate metachromasia.

Color shift reflects interactions with accumulated sulfate-rich compounds.

The staining reaction is a biochemical clue, not a unique cause by itself.

Slide 34 · MLD: Linking substrate to the special stain

Sulfatide-rich deposits

Binding of toluidine blue

Altered dye spectrum

Metachromatic signal

The defining signal derives from dye–substrate interactions.

Interpret staining in combination with tissue distribution and biochemistry.

Schematic

Slide 35 · MLD: Sites in which storage can be detected

Site

Relevant observation

Practical interpretation

Brain white matter

Demyelination, gliosis, macrophages

Central pathology

Peripheral nerve

Metachromatic storage material

Peripheral involvement

Urine

Increased sulfatide excretion

Noninvasive diagnostic support

Slide 36 · MLD: Age at onset shapes the phenotype

Late-infantile, juvenile and adult presentations are recognized.

Earlier disease generally follows a more aggressive course.

Late-onset disease can begin with behavior or performance changes.

Peripheral neuropathy and progressive motor impairment can accompany cerebral disease.

Slide 37 · MLD: Diagnostic triangulation

Progressive neurologic / MRI pattern

Arylsulfatase A testing

Urinary sulfatides

ARSA genotype

A low enzyme result requires careful interpretation.

Independent biochemical or genetic evidence can resolve pseudodeficiency.

Schematic

Slide 38 · MLD: Arylsulfatase A pseudodeficiency

Some otherwise healthy people have low ARSA activity in standard assays.

Biochemical enzyme reduction alone may therefore overcall disease.

Urinary sulfatide analysis and molecular testing improve specificity.

Report incongruent clinical, biochemical and molecular results explicitly.

Slide 39 · Krabbe versus metachromatic leukodystrophy

Discriminator

Krabbe disease

Metachromatic leukodystrophy

Enzyme

GALC

Arylsulfatase A

Key lipid

Psychosine

Sulfatides

Histology

Globoid macrophages

Metachromatic lipid deposits

Peripheral nerves

May be affected

May contain sulfatide deposits

Biochemical pitfalls

GALC pseudodeficiency

ARSA pseudodeficiency

Slide 40 · Teaching vignette: Sulfatide storage

Progressive motor deterioration accompanies diffuse symmetric white matter disease.

Peripheral nerve involvement is present.

Tissue contains vacuolated macrophages and lipid deposits changing toluidine-blue coloration.

Which lysosomal enzyme is deficient?

Slide 41 · Case interpretation: Metachromatic leukodystrophy

Arylsulfatase A deficiency causes sulfatide retention.

Metachromasia explains the characteristic dye reaction.

Urinary sulfatide analysis can reinforce the diagnosis.

Exclude isolated enzyme pseudodeficiency before labeling MLD.

Slide 42 · X-linked adrenoleukodystrophy: Core defect

Loss-of-function pathogenic variants in ABCD1 underlie X-ALD.

ABCD1 encodes a transporter involved in peroxisomal fatty-acid handling.

Defective import impairs catabolism of very-long-chain fatty acids.

Neurologic and adrenal manifestations arise from affected tissues.

Slide 43 · ABCD1 acts at the peroxisomal membrane

Very-long-chain fatty-acid (VLCFA) handling requires the peroxisomal transport system.

ABCD1 dysfunction compromises substrate delivery for beta-oxidation.

VLCFA species accumulate in blood and tissues.

Peroxisome

Fatty-acid load

Schematic — not a diagnostic specimen

Slide 44 · X-ALD: Primary metabolic pathway

ABCD1 loss of function

Impaired peroxisomal import

Reduced VLCFA degradation

VLCFA elevation

Biochemical evidence reflects altered fatty-acid metabolism.

The molecular lesion does not by itself predict an individual phenotype.

Schematic

Slide 45 · X-ALD: Peripheral biochemical signature

Saturated very-long-chain fatty acids are characteristically elevated.

Plasma or serum VLCFA assays can provide supportive biochemical evidence.

C26:0-lysophosphatidylcholine is used in screening or diagnostic workflows.

Molecular identification of ABCD1 variants establishes disease association.

Slide 46 · X-ALD: Cerebral pathology is inflammatory

ABCD1 dysfunction

White matter vulnerability

Myelin loss

Gliosis + lymphocytes

Cerebral X-ALD may show striking inflammatory cell infiltration.

This is a key pathologic distinction from purely storage-dominant processes.

Schematic

Slide 47 · White matter response across three disorders

Feature

Krabbe

MLD

Cerebral X-ALD

Primary insult

Psychosine toxicity

Sulfatide accumulation

Peroxisomal VLCFA defect

Myelin loss

Prominent

Prominent

Prominent

Signature finding

Globoid cells

Metachromatic deposits

Lymphocytic inflammation

Systemic clue

Peripheral nerves

Peripheral nerves

Adrenal cortex

Slide 48 · Adrenal cortical pathology explains hypocortisolism

Adrenal cortical atrophy occurs in X-ALD.

Loss of functional adrenal cortex can produce primary adrenal insufficiency.

Endocrine manifestations are a major diagnostic clue beyond white matter changes.

CNS / peripheral nerve / adrenal cortex

CNS

PNS

Adrenal cortex

One metabolic defect affects several tissues

Schematic — not a diagnostic specimen

Slide 49 · Behavioral symptoms can precede motor disability

In the typical childhood cerebral form, behavioral or school-function changes may be early clues.

Cerebral demyelination can progress to major cognitive and neurologic impairment.

An otherwise isolated behavioral presentation needs context, not reflex labeling.

Adrenal insufficiency increases the specificity of suspicion.

Slide 50 · X-ALD is a phenotypic spectrum

Cerebral disease

Inflammatory white matter involvement

Can progress rapidly

Myeloneuropathy

Progressive long-tract and peripheral involvement

Adrenal involvement

Primary adrenal insufficiency

May appear independently

Timing and combination of organ involvement vary between affected individuals.

Slide 51 · X-ALD: Genotype does not fix phenotype

Different phenotypes can occur within the same family.

ABCD1 variant identity alone does not reliably predict cerebral conversion.

VLCFA concentrations are not a dependable clinical severity scale.

Clinical and MRI monitoring remain relevant after molecular diagnosis.

Slide 52 · X-ALD: Diagnostic integration

Clinical and endocrine findings

Plasma VLCFA / C26:0-LPC

ABCD1 molecular analysis

Brain MRI assessment

Consider other peroxisomal disorders when interpreting abnormal fatty-acid studies.

Interpret variants of uncertain significance cautiously.

Schematic

Slide 53 · Teaching vignette: Cerebral and adrenal disease

A school-age boy develops behavioral decline and neurologic deterioration.

Evaluation detects primary adrenal insufficiency.

White matter is inflamed and depleted of myelin; VLCFAs are elevated.

Which peroxisomal transporter is implicated?

Slide 54 · Case interpretation: X-linked ALD

ABCD1 is the principal molecular defect.

Failure of peroxisomal VLCFA handling causes lipid accumulation.

Inflammatory white matter loss explains cerebral disease.

Adrenal cortical injury provides the endocrine correlation.

Slide 55 · Other leukodystrophies: Diverse primary targets

Not every inherited leukodystrophy is a single-enzyme lysosomal disorder.

GFAP defects implicate astrocyte intermediate filaments.

EIF2B defects implicate translation initiation and the stress response.

PLP1 defects implicate the structure and formation of CNS myelin.

Slide 56 · White matter disease beyond lysosomal storage

GFAP

Astrocyte intermediate filaments

Alexander disease

EIF2B1–5

Protein-translation stress regulation

Vanishing white matter

PLP1

Proteolipid protein of myelin

Pelizaeus–Merzbacher

Distinct cellular origins can converge on loss or inadequate formation of white matter.

Slide 57 · Alexander disease: An astrocytopathy

Pathogenic GFAP variant

Abnormal astrocytic filament homeostasis

Rosenthal fiber accumulation

White matter dysfunction

GFAP-related Alexander disease is typically autosomal dominant.

Histology shows characteristic astrocytic protein inclusions.

Schematic

Slide 58 · Rosenthal fibers: An astrocytic lesion

Rosenthal fibers are characteristic inclusions within astrocytic processes.

They are associated with abnormal GFAP intermediate-filament biology.

The lesion establishes a cellular mechanism different from lipid storage.

Astrocyte / oligodendrocyte stress

Oligodendrocyte

Astrocyte

Schematic — not a diagnostic specimen

Slide 59 · Vanishing white matter: Defective stress regulation

EIF2B pathway variants

Altered translation initiation control

Stress-sensitive glial dysfunction

White matter rarefaction

Fever and minor trauma may trigger neurologic deterioration.

White matter may show marked rarefaction or cystic degeneration.

Schematic

Slide 60 · Vanishing white matter: Clinical clue

Deterioration can be gradual with intermittent episodes of major decline.

Febrile illness or minor head injury can precipitate rapid worsening.

MRI shows characteristic rarefaction of affected cerebral white matter.

A wide age range is possible; Avoid restricting suspicion to children.

Slide 61 · Pelizaeus–Merzbacher: Myelin formation defect

Pathogenic PLP1 variant

Abnormal proteolipid protein function

Deficient CNS myelination

Progressive motor impairment

Classic phenotypes include nystagmus, hypotonia and evolving spasticity.

PLP1-related disorders are X-linked and clinically heterogeneous.

Schematic

Slide 62 · Demyelination and hypomyelination are distinct

Pattern

Interpretation

Example

Demyelination

Loss of myelin previously formed

Cerebral inflammatory X-ALD

Dysmyelination

Formation or maintenance of abnormal myelin

Several metabolic leukodystrophies

Hypomyelination

Insufficient myelin deposition over development

PLP1-associated PMD

Slide 63 · PLP1-related disease forms a severity spectrum

Pelizaeus–Merzbacher disease typically begins in infancy or childhood.

Nystagmus and initial hypotonia are important early clues.

Spasticity and ataxia often evolve with time.

PLP1-associated spastic paraplegia 2 occupies another part of the spectrum.

Slide 64 · Genes, compartments and inheritance

Disorder

Gene / pathway

Typical inheritance

Krabbe

GALC / lysosomal galactolipid

Autosomal recessive

Metachromatic

ARSA / sulfatide catabolism

Autosomal recessive

X-linked ALD

ABCD1 / peroxisome

X-linked

Alexander

GFAP / astrocyte filaments

Autosomal dominant

Vanishing white matter

EIF2B1–5 / translational stress

Autosomal recessive

Pelizaeus–Merzbacher

PLP1 / CNS myelin protein

X-linked

Slide 65 · Mechanism predicts signature findings

Molecular target

Metabolite / protein injury

Affected glial compartment

Tissue pathology

The best discriminating feature may be a tissue inclusion, biochemical analyte or associated organ.

Reason from primary defect to observed morphology, not the reverse alone.

Schematic

Slide 66 · High-yield diagnostic discriminators

Key clue

Leading consideration

Confirmatory direction

Globoid macrophage clusters

Krabbe

GALC / psychosine / GALC genotype

Metachromatic lipid deposits

MLD

ARSA / urinary sulfatides / ARSA genotype

Cerebral inflammation + adrenal signs

X-ALD

VLCFA / ABCD1

Rosenthal fibers in astrocytes

Alexander

GFAP molecular test

Stress-triggered neurologic declines

Vanishing white matter

EIF2B1–5 testing

Early nystagmus + hypomyelination

PLP1-related

PLP1 molecular analysis

Slide 67 · Integrated diagnostic strategy

Progression + neurologic exam

MRI distribution / myelin pattern

Peripheral and systemic screening

Enzyme / metabolite / gene tests

For suspected X-ALD, evaluate adrenal function as well as neurologic disease.

For low lysosomal enzyme activity, exclude pseudodeficiency.

Schematic

Slide 68 · Interpret laboratory results in context

A reduced enzyme activity is not automatically proof of clinical leukodystrophy.

Benign assay pseudodeficiency is recognized for GALC and ARSA.

A genetic variant of uncertain significance is not a molecular diagnosis.

Concordance among phenotype, MRI, metabolites and genotype is essential.

Slide 69 · Pattern-recognition check

Infant + globoid cells

Think GALC deficiency

And psychosine toxicity

Sulfatide-rich deposits

Think ARSA deficiency

And metachromasia

Adrenal failure + cerebral lesions

Think ABCD1 defect

And impaired VLCFA breakdown

These clues prioritize testing; None is a substitute for integrated confirmation.

Slide 70 · Diagnostic exercise: Recognize the cellular target

A young patient has progressive white matter disease.

The family history suggests inherited disease.

Pathology describes astrocytic Rosenthal fibers rather than lipid-filled macrophages.

Which gene and cell type should be prioritized?

Slide 71 · Diagnostic answer: Alexander disease

GFAP encodes an intermediate-filament protein of astrocytes.

Rosenthal fibers indicate altered astrocytic protein homeostasis.

White matter injury can follow dysfunction of supporting glial cells.

Confirm pathogenic GFAP variation in the appropriate setting.

Slide 72 · Diagnostic exercise: Stress-associated deterioration

A patient has a progressive disorder of white matter.

Episodes of abrupt worsening occur after fever or minor trauma.

MRI is described as showing marked white matter rarefaction.

Which molecular pathway offers the strongest explanation?

Slide 73 · Diagnostic answer: Vanishing white matter

Variants affecting eIF2B-related translation initiation are implicated.

Stress response dysregulation explains susceptibility to febrile deterioration.

White matter rarefaction is a major structural clue.

Confirmation depends on appropriate molecular findings.

Slide 74 · Essential clinicopathologic synthesis

Krabbe: Psychosine-related glial toxicity with globoid macrophages.

MLD: Sulfatide storage with metachromatic deposits and gliosis.

X-ALD: ABCD1-associated VLCFA defect with inflammatory white matter pathology and adrenal involvement.

Alexander, vanishing white matter and PLP1 disease illustrate non-enzymatic mechanisms.

Slide 75 · Selected references

Robbins, Cotran & Kumar. Pathologic Basis of Disease, 11th ed., Chapter 28.

GeneReviews: Krabbe Disease; Arylsulfatase A Deficiency; X-Linked Adrenoleukodystrophy.

GeneReviews: Alexander Disease; Vanishing White Matter; PLP1-Related Disorders.

Complete bibliographic details, dates and URLs are retained in speaker notes.